Related Experiment Video
Updated: May 26, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
GSTM1, GSTT1 and GSTP1 gene polymorphism in polymorphous light eruption
M Zirbs1, C Pürner, J T M Buters
1Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. michael.zirbs@lrz.tu-muenchen.de
Summary
Glutathione S-transferase (GST) gene variants do not appear to protect against polymorphous light eruption (PLE). This study found no significant association between GST isoenzymes or polymorphisms and PLE development in patients compared to controls.
Area of Science:
- Dermatology
- Genetics
- Immunology
Background:
- Polymorphous light eruption (PLE) is a common photodermatosis linked to genetic predisposition and immune reactions to UV-induced antigens.
- Reactive oxygen species (ROS) play a role in PLE pathogenesis, with glutathione S-transferases (GSTs) offering cellular protection against ROS.
- GST enzyme variants may affect the detoxification of UV-induced skin antigens, potentially influencing PLE development.
Purpose of the Study:
- To investigate the association between glutathione S-transferase (GST) gene variants (GSTM1, GSTT1, GSTP1) and their potential protective or predisposing effects on polymorphous light eruption (PLE).
Main Methods:
- Genotyping of GSTM1, GSTT1, and GSTP1 gene polymorphisms in 29 PLE patients and 144 healthy controls.
- Analysis of the relationship between specific GST isoenzymes/polymorphisms and the presence or absence of PLE.
- Diagnosis of PLE confirmed by characteristic clinical features.
Main Results:
- No statistically significant association was found between functional polymorphisms of the GST gene family and polymorphous light eruption (PLE).
- The prevalence of specific GST isoenzymes and polymorphisms did not differ between PLE patients and the control group.
- Previous findings suggesting a protective role for GSTP1 Val(105) against PLE were not replicated in this study.
Conclusions:
- The study data do not support a protective role for glutathione S-transferase (GST) isoenzymes or polymorphisms against polymorphous light eruption (PLE).
- Specific GST genotypes, including GSTM1, GSTT1, and GSTP1 (and their SNPs), show no relevant association with the pathogenesis of PLE.
- Further research may be needed to elucidate the genetic factors contributing to PLE susceptibility.
More Related Videos
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:33Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...